|Dr. Charles S. Ryan||CEO & Director||447.64k||N/A||1964|
|Dr. Daniel L. Alkon||Pres & Chief Scientific Officer||300k||N/A||1942|
|Mr. Robert Weinstein||CFO, Exec. VP, Sec. & Treasurer||329.65k||N/A||1960|
|Dr. Michael Ciraolo||Gen. Counsel & COO||N/A||N/A||1973|
|Mr. Jeffrey Benison||Director of Corp. Communications||N/A||N/A||N/A|
Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.
Neurotrope, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.